APA (7th ed.) Citation

LF, S. G., J, B., SK, T., HC, H., L, P., R, V., . . . KA, P. (2023). Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: Results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). The British journal of dermatology, 189(5), 540. https://doi.org/10.1093/bjd/ljad252

Chicago Style (17th ed.) Citation

LF, Stein Gold, et al. "Comparison of Risankizumab and Apremilast for the Treatment of Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy: Results from a Randomized, Open-label, Assessor-blinded Phase IV Study (IMMpulse)." The British Journal of Dermatology 189, no. 5 (2023): 540. https://doi.org/10.1093/bjd/ljad252.

MLA (9th ed.) Citation

LF, Stein Gold, et al. "Comparison of Risankizumab and Apremilast for the Treatment of Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy: Results from a Randomized, Open-label, Assessor-blinded Phase IV Study (IMMpulse)." The British Journal of Dermatology, vol. 189, no. 5, 2023, p. 540, https://doi.org/10.1093/bjd/ljad252.